👤 Baiwan Zhou

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
1335
Articles
847
Name variants
Also published as: Aiping Zhou, Aiwu Zhou, Alicia Y Zhou, An Zhou, Ang Zhou, Anna Y Zhou, Annan Zhou, Ao Zhou, Aojia Zhou, Aoshuang Zhou, Apei Zhou, Bao-Sen Zhou, Baohua Zhou, Baojuan Zhou, Baosen Zhou, Beixian Zhou, Beiyi Zhou, Bin Zhou, Bincheng Zhou, Bing Zhou, Bingbing Zhou, Binghai Zhou, Bingqian Zhou, Bingqing Zhou, Bingying Zhou, Binhua P Zhou, Binhua Zhou, Birong Zhou, Bo Zhou, Bo-Ya Zhou, Bo-Yang Zhou, Bubo Zhou, C Zhou, C-J Zhou, Can Zhou, Carl Zhou, Cefan Zhou, Chang Zhou, Chang-Yin Zhou, Changfan Zhou, Changhua Zhou, Changqi Zhou, Changrui Zhou, Changshuai Zhou, Changwen Zhou, Chao Zhou, Chen-Hui Zhou, Chen-Liang Zhou, Chenchen Zhou, Cheng Zhou, Chengji J Zhou, Chenhao Zhou, Chenkang Zhou, Chenqi Zhou, Chenxia Zhou, Chong Zhou, Chong-zhi Zhou, Chongwei Zhou, ChuHuan Zhou, Chuan-Min Zhou, Chuan-Wei Zhou, Chuan-Xiang Zhou, Chuan-chuan Zhou, Chuanen Zhou, Chuanman Zhou, Chuhao Zhou, Chun-Man Zhou, Chun-Ni Zhou, Chunlei Zhou, Chunlin Zhou, Chunni Zhou, Chunxian Zhou, Chunxiu Zhou, Chunyu Zhou, Chunzhuang Zhou, Chuyu Zhou, Cui Zhou, Cuiqi Zhou, Da Zhou, Daijun Zhou, Daizhan Zhou, Dan Zhou, Danmei Zhou, Danxia Zhou, Dao Zhou, David Zhou, Dawei Zhou, Daxin Zhou, Degang Zhou, Dejun Zhou, Dezheng Zhou, Dingan Zhou, Dingzi Zhou, Dong-Sheng Zhou, Dongdong Zhou, Donger Zhou, Dongfang Zhou, Donghai Zhou, Dongjie Zhou, Dongmei Zhou, Dongsheng Zhou, Duanfang Zhou, Duo-Qi Zhou, Duoqi Zhou, Enchen Zhou, Ershun Zhou, F Zhou, Fachen Zhou, Fan Zhou, Fanfan Zhou, Fang Zhou, Fangfang Zhou, Fangli Zhou, Fangting Zhou, Fei Zhou, Feixue Zhou, Feiye Zhou, Feng Zhou, Feng-Quan Zhou, Fenghua Zhou, Fengrui Zhou, Fengyun Zhou, Fenling Zhou, Fu-Ling Zhou, Fude Zhou, Fuling Zhou, Fusheng Zhou, Fuxiang Zhou, Fuyou Zhou, G Zhou, Gang Zhou, Grace Guoying Zhou, Guangji Zhou, Guangjun Zhou, Guangming Zhou, Guangqian Zhou, Guangzhou Zhou, Gui-Feng Zhou, Guifeng Zhou, Guiju Zhou, Guili Zhou, Guiting Zhou, Guo Zhou, Guo-Kun Zhou, Guohong Zhou, Guohua Zhou, Guoli Zhou, Guoyu Zhou, Guyue Zhou, H Zhou, Haibo Zhou, Haihong Zhou, Haihua Zhou, Haijing Zhou, Haimei Zhou, Hairui Zhou, Haixu Zhou, Haiyan Zhou, Haiyuan Zhou, Haiyue Zhou, Han Zhou, Hang Zhou, Hang-Yu Zhou, Hangfan Zhou, Hanshen Zhou, Hanxiao Zhou, Hao Zhou, Hao-Min Zhou, Haobo Zhou, Haonan Zhou, Haoxiong Zhou, Haoyuan Zhou, He Zhou, Helen Zhou, HengCui Zhou, Heying Zhou, Hong Zhou, Hong-Yu Zhou, Honghong Zhou, Hongji Zhou, Honglei Zhou, Hongli Zhou, Hongmei Zhou, Hongmin Zhou, Hongshan Zhou, Hongwei Zhou, Hongwen Zhou, Hongyan Zhou, Hou-De Zhou, Hu Zhou, Hua Ying Zhou, Hua Zhou, Hua-Bang Zhou, Huadong Zhou, Huaijun Zhou, Huamao Zhou, Huan Zhou, Huangao Zhou, Huanjin Zhou, Huanyu Zhou, Huaqiang Zhou, Hui Zhou, Hui-Fen Zhou, Huifang Zhou, Huifen Zhou, Huihui Zhou, Huimin Zhou, Huinian Zhou, Huiqiang Zhou, Huiwen Zhou, J Zhou, Jeff Xiwu Zhou, Ji Zhou, Ji-Chao Zhou, Ji-Ying Zhou, Jia Zhou, Jia-Guo Zhou, Jia-le Zhou, Jiahe Zhou, Jiahua Zhou, Jiajie Zhou, Jiale Zhou, Jiamei Zhou, Jian Zhou, Jian-Peng Zhou, JianJiang Zhou, Jianan Zhou, Jianfen Zhou, Jianfeng Zhou, Jiang-Ning Zhou, Jiangfei Zhou, Jianghao Zhou, Jianghong Zhou, Jianghui Zhou, Jianglin Zhou, Jiangqiao Zhou, Jianguo Zhou, Jianhua Zhou, Jianling Zhou, Jianmin Zhou, Jianqing Zhou, Jianshe Zhou, Jianwei Zhou, Jianying Zhou, Jianzhong Zhou, Jiaqi Zhou, Jiaru Zhou, Jiawang Zhou, Jiawei Zhou, Jiawen Zhou, Jiaxi Zhou, Jiaxiang Zhou, Jiaxin Zhou, Jiayan Zhou, Jiayi Zhou, Jiayin Zhou, Jie Zhou, Jiechao Zhou, Jiefu Zhou, Jieru Zhou, Jieyan Zhou, Jieyu Zhou, Jin Zhou, Jin-Ting Zhou, Jin-Yong Zhou, JinQiu Zhou, Jing Zhou, Jing-Wei Zhou, Jing-Xuan Zhou, Jingbo Zhou, Jingjie Zhou, Jingjing Zhou, Jingjun Zhou, Jingpei Zhou, Jingqi Zhou, Jingwen Zhou, Jingyi Zhou, Jingyu Zhou, Jingyuan Zhou, Jinting Zhou, Jinyi Zhou, Jiuyao Zhou, Jiyong Zhou, John Zhou, Ju Zhou, Juan Zhou, Juanjuan Zhou, Jue-Yu Zhou, Julian Q Zhou, Jun Zhou, Jun-Min Zhou, Jun-Ying Zhou, Jun-Yu Zhou, Jundong Zhou, Junfeng Zhou, Jungu Zhou, Junguo Zhou, Junhe Zhou, Junjie Zhou, Junjun Zhou, Junting Zhou, Junya Zhou, Junyu Zhou, Justin Zhou, Juying Zhou, Kaicheng Zhou, Kaixia Zhou, Kaixin Zhou, Kaiyu Zhou, Kan Zhou, Ke Zhou, Kecheng Zhou, Kefu Zhou, Kejin Zhou, Kexun Zhou, Lamei Zhou, Lan Zhou, Lang Zhou, Lanlan Zhou, Lanping Zhou, Lanqi Zhou, Laura Y Zhou, Le Zhou, Lei Zhou, Lei-Lei Zhou, Li Zhou, Li-Jun Zhou, Liang Zhou, Liangdong Zhou, Liangfu Zhou, Liangrui Zhou, Liangxue Zhou, Liangyu Zhou, Libin Zhou, Libing Zhou, Libo Zhou, Liche Zhou, Lihong Zhou, Lihuan Zhou, Lijun Zhou, Lili Zhou, Limin Zhou, Lin Zhou, Lina Zhou, Linda Zhou, Ling Zhou, Ling-Yun Zhou, Linglin Zhou, Lingshan Zhou, Lingyi Zhou, Lingyun Zhou, Linjun Zhou, Linnan Zhou, Linran Zhou, Lipeng Zhou, Liqun Zhou, Lisha Zhou, Lisheng Zhou, Liting Zhou, Liufang Zhou, Liuqing Zhou, Liuxin Zhou, Lixin Zhou, Liye Zhou, Long Zhou, Lu Zhou, Lufang Zhou, Luling Zhou, Luming Zhou, Lunni Zhou, Luo-Qi Zhou, Luting Zhou, M M Zhou, Maoge Zhou, Maotian Zhou, Mei Zhou, Meijing Zhou, Meilan Zhou, Meiqi Zhou, Meirong Zhou, Meiyi Zhou, Meng-Tao Zhou, Meng-Yao Zhou, Menghua Zhou, Mengkai Zhou, Menglong Zhou, Mengna Zhou, Mengqi Zhou, Mengqian Zhou, Mengze Zhou, Mi Zhou, Miao Zhou, Min Zhou, Ming Zhou, Ming-Ju Zhou, Ming-Ming Zhou, Ming-Sheng Zhou, Mingfeng Zhou, Minglei Zhou, Minglian Zhou, Mingmei Zhou, Mingming Zhou, Mingping Zhou, Mingqi Zhou, Minling Zhou, Minyi Zhou, Molin Zhou, Na Zhou, Nan Zhou, Neng Zhou, Ni Zhou, Nian Zhou, Nianwei Zhou, Ning Zhou, Ningying Zhou, Niuniu Zhou, P Zhou, Pei Zhou, Peng Zhou, Penghui Zhou, Pijun Zhou, Ping Zhou, Ping-Kun Zhou, Pingkun Zhou, Pingxi Zhou, Pingxin Zhou, Puhui Zhou, Q Zhou, Qi Zhou, Qian Zhou, Qiang Zhou, Qianxin Zhou, Qiao Zhou, Qiaoxia Zhou, Qidong Zhou, Qin Zhou, Qin-Yi Zhou, Qing Zhou, Qing-Bing Zhou, Qing-Qing Zhou, Qingbing Zhou, Qingbo Zhou, Qingchun Zhou, Qinghua Zhou, Qingniao Zhou, Qingnv Zhou, Qingping Zhou, Qingtong Zhou, Qingxin Zhou, Qingyu Zhou, Qiong Zhou, Qiu-Min Zhou, Qiu-Zhi Zhou, Qiyang Zhou, Qiyin Zhou, Quan Zhou, Qun Zhou, R B Zhou, Ranran Zhou, Raorao Zhou, Ren Zhou, Rong Zhou, Rong-Yan Zhou, Rongbin Zhou, Rongjia Zhou, Rongxian Zhou, Rongxuan Zhou, Rongyan Zhou, Rouxi Zhou, Ru Zhou, Ruchen Zhou, Rui Zhou, Ruihai Zhou, Ruijun Zhou, Ruimei Zhou, Ruisi Zhou, Runjin Zhou, Ruyi Zhou, S A Zhou, S R Zhou, S Zhou, S-G Zhou, Sa Zhou, Sanshun Zhou, Sha Zhou, Shanshan Zhou, Shao-Lai Zhou, Shaobo Zhou, Shaoli Zhou, Shaolong Zhou, Sheng-Nan Zhou, Shenghua Zhou, Shenghui Zhou, Shengwen Zhou, Shengyang Zhou, Shengyi Zhou, Shenping Zhou, Shiao Zhou, Shibo Zhou, Shiyi Zhou, Shu Zhou, Shuaishuai Zhou, Shuaiyang Zhou, Shuang Zhou, Shuling Zhou, Shumin Zhou, Shun Zhou, Shuo Zhou, Si Zhou, Si-Qi Zhou, Siquan Zhou, Sirui Zhou, Song Zhou, Songhui Zhou, Sufang Zhou, Sumei Zhou, Suqing Zhou, Suzhen Zhou, T Zhou, Tai-Cheng Zhou, Taimei Zhou, Tao Zhou, Tengxiao Zhou, Ti Zhou, Tian-Li Zhou, Tianhua Zhou, Tianqiong Zhou, Tianrong Zhou, Tianxing Zhou, Tianyan Zhou, Tianyu Zhou, Tiger Zhou, Ting Zhou, Tingting Zhou, Tong Zhou, Vincent Zhou, W Zhou, Wan-hao Zhou, Wang Zhou, Wei Zhou, Weihua Zhou, Weihui Zhou, Weijiao Zhou, Weijie Zhou, Weiming Zhou, Weinan Zhou, Weiqiang Zhou, Weishang Zhou, Weiwei Zhou, Weiying Zhou, Wen Zhou, Wen-Chao Zhou, Wen-Hao Zhou, Wen-Jie Zhou, Wen-Quan Zhou, Wenbin Zhou, Wenbo Zhou, Wenchao Zhou, Wenfang Zhou, Wenhao Zhou, Wenjie Zhou, Wenjing Zhou, Wenke Zhou, Wenqing Zhou, Wenrong Zhou, Wenwen Zhou, Wenxing Zhou, Wenyu Zhou, Wenzong Zhou, Wesley Zhou, Wu Zhou, Wuduo Zhou, Wuyuan Zhou, X F Zhou, X Q Zhou, X-T Zhou, Xi Zhou, Xia Zhou, Xia-Bo Zhou, Xiang Zhou, Xiangda Zhou, Xiangdong Zhou, Xianghai Zhou, Xiangrong Zhou, Xianguo Zhou, Xiangyu Zhou, Xiangyuan Zhou, Xianhu Zhou, Xianhua Zhou, Xianhui Zhou, Xianjing Zhou, Xianliang Zhou, Xianxiao Zhou, Xiao Zhou, Xiao-Hai Zhou, Xiao-Ting Zhou, Xiao-Yu Zhou, Xiaobo Zhou, Xiaochuan Zhou, Xiaochun Zhou, Xiaofeng Zhou, Xiaohai Zhou, Xiaohan Zhou, Xiaohui Zhou, Xiaojing Zhou, Xiaolei Zhou, Xiaoli Zhou, Xiaolin Zhou, Xiaoling Zhou, Xiaomao Zhou, Xiaoming Zhou, Xiaonan Zhou, Xiaopu Zhou, Xiaoqian Zhou, Xiaorong Zhou, Xiaorui Zhou, Xiaoshu Zhou, Xiaosu Zhou, Xiaotong Zhou, Xiaowen Zhou, Xiaoxi Zhou, Xiaoxia Zhou, Xiaoxue Zhou, Xiaoyan Zhou, Xiaoye Zhou, Xiaoying Zhou, Xiaozhong Zhou, Xidan Zhou, Xin Tong Zhou, Xin Zhou, Xin-Rong Zhou, Xin-Yu Zhou, Xin-Yue Zhou, Xingtao Zhou, Xinhong Zhou, Xinhua Zhou, Xinming Zhou, Xinyan Zhou, Xinyao Zhou, Xinyi Zhou, Xinyue Zhou, Xinzhi Zhou, Xiqiu Zhou, Xiu-Ping Zhou, Xiuhong Zhou, Xiuling Zhou, Xiuping Zhou, Xiuteng Zhou, Xiyi Zhou, Xu Yu Zhou, Xu Zhou, Xu-Hua Zhou, Xuan Zhou, Xuanchen Zhou, Xuchang Zhou, Xue Dong Zhou, Xue Zhou, Xue-Yan Zhou, Xuedong Zhou, Xuefeng Zhou, Xuejie Zhou, Xueli Zhou, Xueliang Zhou, Xueqin Zhou, Xueqing Zhou, Xueshi Zhou, Xujie Zhou, Xun Zhou, Xuyu Zhou, Y J Zhou, Y Zhou, Y-L Zhou, Yachuan Zhou, Yadi Zhou, Yahui Zhou, Yajun Zhou, Yan Zhou, Yan-Yan Zhou, Yanbing Zhou, Yandong Zhou, Yanfen Zhou, Yang Zhou, Yangbo Zhou, Yangying Zhou, Yanhao Zhou, Yanheng Zhou, Yanhua Zhou, Yanjiao Zhou, Yanjie Zhou, Yanli Zhou, Yanling Zhou, Yanmeng Zhou, Yanqiu Zhou, Yanrong Zhou, Yanyi Zhou, Yao Zhou, Yaping Zhou, Yaqi Zhou, Yating Zhou, Yeyun Zhou, Yi Zhou, Yi-Hui Zhou, Yi-Jiang Zhou, Yichao Zhou, Yidan Zhou, Yifa Zhou, Yifeng Zhou, Yinan Zhou, Ying Zhou, Ying-Hui Zhou, Yinghui Zhou, Yingjie Zhou, Yingmin Zhou, Yingshi Zhou, Yiqing Zhou, Yitian Zhou, Yong Zhou, Yong-Gang Zhou, Yong-Hui Zhou, Yong-an Zhou, Yongbing Zhou, Yongcan Zhou, Yonghua Zhou, Yongjian Zhou, Yongqiang Zhou, Yongtao Zhou, Yongxin Zhou, Yongzhi Zhou, You Lang Zhou, You Zhou, You-Li Zhou, Youping Zhou, Yu Zhou, Yu-Bao Zhou, Yu-Ning Zhou, Yu-Qi Zhou, Yuan Zhou, Yuanyuan Zhou, Yubin Zhou, Yudong Zhou, Yue Zhou, Yueping Zhou, Yuetao Zhou, Yufei Zhou, Yuhan Zhou, Yuhuan Zhou, Yujia Zhou, Yujie Zhou, Yun Zhou, Yun-Fei Zhou, Yun-Tao Zhou, Yunfang Zhou, Yunfeng Zhou, Yunhui Zhou, Yunqian Zhou, Yunxia Zhou, Yunxiang Zhou, Yunyun Zhou, Yunzhen Zhou, Yuqi Zhou, Yuqiao Zhou, Yuqing Zhou, Yuqiu Zhou, Yushan Zhou, Yuting Zhou, Yutong Zhou, Yuxin Zhou, Yuzhi Zhou, Zechen Zhou, Zefeng Zhou, Zenghui Zhou, Zengyuan Zhou, Zengzi Zhou, Zewei Zhou, Zhan Zhou, Zhaokai Zhou, Zhechong Zhou, Zhen Zhou, Zheng Zhou, Zheng-Jun Zhou, Zheng-Yang Zhou, Zhengyang Zhou, Zhengzhong Zhou, Zhenhua Zhou, Zhenlei Zhou, Zhenying Zhou, Zhenyu Zhou, Zheyi Zhou, Zhi Dong Zhou, Zhi Zhou, Zhi-Dong Zhou, Zhi-Gang Zhou, Zhi-Hang Zhou, Zhi-Jiao Zhou, Zhi-Xiang Zhou, Zhi-Yong Zhou, Zhibo Zhou, Zhicheng Zhou, Zhifeng Zhou, Zhiguang Zhou, Zhihang Zhou, Zhihao Zhou, Zhiheng Zhou, Zhihui Zhou, Zhijiao Zhou, Zhijun Zhou, Zhimin Zhou, Zhipeng Zhou, Zhiqin Zhou, Zhiqun Zhou, Zhiwei Zhou, Zhixiang Zhou, Zhiyi Zhou, Zhiyong Zhou, Zhiyu Zhou, Zhongbo Zhou, Zhongjiang Zhou, Zhongkai Zhou, Zhongqiu Zhou, Zhongtao Zhou, Zhongxing Zhou, Zhongyin Zhou, Zhou Zhou, Zhu Zhou, Zhuoming Zhou, Zi-Yang Zhou, Zi-Yi Zhou, Zihan Zhou, Zihao Zhou, Zihua Zhou, Zijun Zhou, Zili Zhou, Ziliang Zhou, Zilin Zhou, Zilong Zhou, Zipeng Zhou, Ziqing Zhou, Ziwei Zhou, Ziyan Zhou, Ziyue Zhou, Ziyun Zhou, Zongkai Zhou, Zunchun Zhou, Zuomin Zhou, Zuoqiong Zhou, Zuping Zhou
articles
Jing Zhou, Benjamin H Wang, Jiangning Yu +9 more · 2026 · CNS neuroscience & therapeutics · Wiley · added 2026-04-24
Post-stroke seizures are a common and debilitating complication with limited therapeutic options, underscoring the need to identify novel molecular targets. Disruption of chloride homeostasis via impa Show more
Post-stroke seizures are a common and debilitating complication with limited therapeutic options, underscoring the need to identify novel molecular targets. Disruption of chloride homeostasis via impaired potassium chloride cotransporter 2 (KCC2) activity is a key driver of neuronal hyperexcitability. While microglia are a predominant source of brain-derived neurotrophic factor (BDNF) in the acute phase after brain injury, the role of microglial BDNF and its signaling in KCC2 dysregulation and early post-stroke seizure susceptibility remain poorly defined. Using a middle cerebral artery occlusion-reperfusion (MCAO-R) mouse model and oxygen-glucose deprivation/reoxygenation (OGD/R) in hippocampal neurons, we assessed KCC2 function, neuronal excitability, and seizure susceptibility. Pharmacological tools, including the microglial inhibitor minocycline, the TrkB antagonist K252a, the loop diuretic furosemide (FUR), repurposed here as a KCC2-stabilizing agent, and the KCC2 activator CLP290, were employed. Techniques included immunofluorescence, Western blotting, patch-clamp electrophysiology, electroencephalography (EEG), and behavioral seizure assessment. MCAO-R and OGD/R significantly reduced membrane KCC2 expression, leading to a depolarizing shift in the GABA equilibrium potentials (E Our findings identify microglia-derived BDNF/TrkB signaling as a critical upstream pathway mediating KCC2 dysfunction in early post-stroke seizure. Targeting this axis by inhibiting microglial activation, blocking TrkB, or directly enhancing KCC2 function with activators like CLP290 represents a promising therapeutic strategy for stroke-related epilepsy. Show less
📄 PDF DOI: 10.1002/cns.70795
BDNF
Tianyi Xu, Yang Jing Zheng, Sabrina Wong +5 more · 2026 · Asian journal of psychiatry · Elsevier · added 2026-04-24
A converging mechanistic theme across mental disorders involves impaired neuroplasticity and reduced brain-derived neurotrophic factor (BDNF). Glucagon-like peptide-1 receptor agonists (GLP-1RAs), use Show more
A converging mechanistic theme across mental disorders involves impaired neuroplasticity and reduced brain-derived neurotrophic factor (BDNF). Glucagon-like peptide-1 receptor agonists (GLP-1RAs), used for type 2 diabetes and obesity, have shown neuroprotective potential, but whether these effects are mediated by BDNF is unclear. This systematic review synthesised molecular evidence linking GLP-1RA administration to BDNF changes and evaluated their contribution to illness progression in neurodegenerative and psychiatric disorders. A systematic search of PubMed, Ovid and Google Scholar from inception to September 6, 2025, identified studies reporting BDNF-related outcomes following GLP-1RA treatment. Eligible studies included primary in vivo or in vitro research on GLP-1RAs in models of neurodegenerative or psychiatric disorders. Risk of bias was assessed using SYRCLE and QUIN tools. The initial search yielded 300 records, of which 18 met the inclusion criteria. Across these studies, GLP-1RAs consistently enhanced BDNF expression and signalling in models of diabetes, neurodegeneration and neurotoxicity, with diabetic models included for their relevance to GLP-1RA pharmacology and shared neuroinflammatory pathway. Reported increases in BDNF expression ranged from 76 % to 377 %, correlating with improved synaptic plasticity, cognition and neuronal survival. In vitro, GLP-1 and exendin-4 increased BDNF expression and axonal transport even under Aβ oligomer exposure. While most neuroprotection aligned with BDNF upregulation, some effects occurred independently through alternative pathways. GLP-1RAs upregulate BDNF in preclinical models, supporting its role as a key mediator of neuroprotection. Despite some BDNF-independent actions, the consistent restoration of neurotrophic support positions BDNF as a central pathway for disease modification. Show less
no PDF DOI: 10.1016/j.ajp.2026.104870
BDNF bdnf brain-derived neurotrophic factors glp-1 receptor agonists neurodegenerative disorders neuroplasticity psychiatric disorders
Caifeng Gong, Shuhui You, Qi Zhang +10 more · 2026 · Journal for immunotherapy of cancer · added 2026-04-24
This study was conducted to assess the clinical significance of programmed cell death-ligand 1 (PD-L1)-positive circulating tumor cells (CTCs) as predictive biomarkers for the efficacy of PD-(L)1 inhi Show more
This study was conducted to assess the clinical significance of programmed cell death-ligand 1 (PD-L1)-positive circulating tumor cells (CTCs) as predictive biomarkers for the efficacy of PD-(L)1 inhibitor-based treatment in advanced hepatocellular carcinoma (HCC). We enrolled 59 patients with unresectable HCC who received immunotherapy-based treatment and analyzed CTCs, PD-L1 CTCs were detected in 86.4% (51/59) of patients, with a PD-L1-positive rate of 83.7% (41/49). Compared with the "PD-L1 PD-L1 Show less
📄 PDF DOI: 10.1136/jitc-2025-013381
BDNF
Haojie Ni, Yiyi Xiong, Min Liu +14 more · 2026 · Phytomedicine : international journal of phytotherapy and phytopharmacology · Elsevier · added 2026-04-24
The pathological mechanism of Alzheimer's disease (AD) is complex. The binding of Aβ to α7 nicotinic acetylcholine receptor (α7nAChR) contributes to neuronal damage. Sinomenine (SIN) is an alkaloid ex Show more
The pathological mechanism of Alzheimer's disease (AD) is complex. The binding of Aβ to α7 nicotinic acetylcholine receptor (α7nAChR) contributes to neuronal damage. Sinomenine (SIN) is an alkaloid extracted from the traditional Chinese medicine Qingfengteng (Sinomenium acutum). The anti-inflammatory, antioxidant, and immunomodulatory effects of SIN were confirmed to be closely associated with the α7nAChR. This study aimed to investigate whether α7nAChR serves as a pharmacological target of SIN against AD, and to evaluate the neuroprotective effects of SIN both in vivo and in vitro, focusing on the α7nAChR/Nrf2/Keap1 signaling pathway. In this study, the effects of SIN in both APP/PS1 transgenic mice and SH-SY5Y cells subjected to Aβ1-42-induced injury were assessed. The selective antagonist α-bungarotoxin ‌(α-BTX), the agonist nicotine (Nic) of α7nAChR, and α7nAChR siRNA were employed. The cognitive function, Aβ deposition, synaptic plasticity markers, the tau protein phosphorylation, mitochondrial membrane potential, oxidative stress and the α7nAChR/Nrf2/Keap1 signaling pathway were analyzed in vivo and/or in vitro. SIN significantly enhanced learning and memory abilities in APP/PS1 mice, reduced Aβ plaque deposition and synaptic dysfunction, and inhibited hyperphosphorylation of tau protein and oxidative stress in the brain. In Aβ1-42-induced neuronal injury model, SIN alleviated apoptosis, increased BDNF and ACh levels, inhibited mitochondrial damage, stabilized calcium homeostasis, and suppressed oxidative stress. Meanwhile, SIN disrupted Nrf2-Keap1 binding to promote the Nrf2/HO-1 signaling pathway. Nevertheless, SIN effects above were inhibited by α-BTX. The knockdown of α7nAChR in vitro significantly promoted Nrf2/HO-1 pathway and BDNF expression. SIN exerts neuroprotective effect in APP/PS1 transgenic mice and Aβ1-42-induced neuronal injury by inhibiting oxidative stress via α7nAChR/Nrf2/Keap1 pathway. This study provides evidence for α7nAChR as a new target and the clinical application potential of SIN in AD treatment. Show less
no PDF DOI: 10.1016/j.phymed.2026.157779
BDNF alzheimer's disease antioxidant inflammation neuroprotection oxidative stress pathology sinomenine
Jie Chen, Xuefen Wu, Qian ZHANG +8 more · 2026 · Chinese journal of natural medicines · Elsevier · added 2026-04-24
Chronic heart failure (CHF) impairs cognitive function. Xijiaqi Formula (XJQ), a traditional Chinese medicine (TCM) used clinically to treat CHF, demonstrates potential for improving cognition in CHF Show more
Chronic heart failure (CHF) impairs cognitive function. Xijiaqi Formula (XJQ), a traditional Chinese medicine (TCM) used clinically to treat CHF, demonstrates potential for improving cognition in CHF patients. However, its precise mechanism in treating post-CHF cognitive dysfunction remains unclear. This study systematically investigates XJQ's effects on post-CHF cognitive dysfunction and the underlying mechanisms. The components of XJQ were identified through liquid chromatography-mass spectrometry. CHF was induced in rats via ligation of the left anterior descending coronary artery, followed by six weeks of XJQ treatment. Cardiac function was evaluated through echocardiography and hemodynamic parameters, while cognitive function was assessed using Morris water maze (MWM) and open field tests (OFT). XJQ treatment enhanced both cardiac and cognitive functions in CHF rats. Network pharmacology identified 12 core active components of XJQ and indicated its effect on cognitive dysfunction involved regulating synapses, inflammation, and phosphodiesterase 4 (PDE4)-dependent cyclic adenosine monophosphate (cAMP) signaling. XJQ inhibited microglial and astrocyte activation, decreased proinflammatory cytokines, and mitigated neuronal damage. Notably, XJQ promoted synaptic repair and dendritic growth by downregulating PDE4 and upregulating cAMP, protein kinase A (PKA), cAMP-response element binding protein (CREB), brain-derived neurotrophic factor (BDNF), PSD95, and synapsin I levels. Molecular docking and Bio-layer interferometry assays confirmed direct binding of quercetin, kaempferol, isorhamnetin, and darutoside to PDE4. In conclusion, XJQ alleviates neuroinflammation and enhances synaptic plasticity to improve cognitive dysfunction in CHF rats via the PDE4/cAMP/PKA/CREB signaling pathway. These findings provide valuable insight into the heart-brain axis. Show less
no PDF DOI: 10.1016/S1875-5364(26)61078-3
BDNF chronic heart failure cognitive dysfunction neuroinflammation neuroplasticity traditional chinese medicine
Fang Chen, Ning Jiang, Muhammad Noman Khan +8 more · 2026 · Life sciences in space research · Elsevier · added 2026-04-24
Growing evidence highlights that long-term orbital flight may lead to structural changes in brains and cognitive impairments in astronauts. However, effective strategies to counteract these effects re Show more
Growing evidence highlights that long-term orbital flight may lead to structural changes in brains and cognitive impairments in astronauts. However, effective strategies to counteract these effects remain limited. Compound Gastrodia elata Formula (CGEF), composed of Gastrodia elata Bl., Polygonatum sibirium Red., and Poria cocos (Schw.) Wolf has been shown to improve learning and memory. The present study aimed to evaluate the effects and underlying mechanisms of CGEF in attenuating cognitive deficiency induced by simulated weightlessness in mice. A cognitive impairment model was induced in mice using Hindlimb unloading (HU) method. Cognitive function was assessed through Object recognition test (ORT), the Morris water maze (MWM), and the Step-down Test (SDT). Serum and hippocampus levels of inflammatory markers, including Interleukin-1 beta (IL-1β), Tumor Necrosis Factor alpha (TNF-α), and Interleukin-6 (IL-6) were evaluated using ELISA. Neurotransmitter concentrations in the hippocampus and cortex were measured using LC-MS/MS. While Brain-derived neurotrophic factor (BDNF) / Tropomyosin receptor kinase B (TrkB) protein expression signaling pathway in hippocampus was evaluated by western blot. Results showed that CGEF treatment significantly reversed the memory deficits induced by four weeks of HU exposure. Furthermore, CGEF treatment markedly suppressed the production of inflammatory factors. It also assisted in the recovery of neurotransmitter balance and regulated tryptophan metabolism to improve cognitive disorder. Western blotting analysis revealed that CGEF treatment upregulated the expression of Synaptophysin, Postsynaptic density 95 proteins, while also activating the brain-derived neurotrophic factor-Tropomyosin receptor kinase B pathway. These findings suggest that CGEF has substantial potential for development as an aerospace health product to improve memory decline associated with spaceflight. Show less
no PDF DOI: 10.1016/j.lssr.2025.08.004
BDNF astrobiology cognitive function cognitive impairment neuroprotection neuroscience space medicine weightlessness
Kai Zhang, Sijia Zhu, Na Xing +16 more · 2026 · British journal of pharmacology · Blackwell Publishing · added 2026-04-24
Chronic pain, marked by nociceptive sensitization and maladaptive neuroplasticity, affects 30% of the global population with escalating socioeconomic burdens. Epidemiological data show a 2-3-fold incr Show more
Chronic pain, marked by nociceptive sensitization and maladaptive neuroplasticity, affects 30% of the global population with escalating socioeconomic burdens. Epidemiological data show a 2-3-fold increase in neuropsychiatric co-morbidities among individuals with chronic pain, where epigenetic dysregulation serves as a key mechanism linking ongoing pain to emotional disorders. This review systematically explores epigenetic signatures in supraspinal integration hubs, notably the limbic-paralimbic networks and prefrontal regulatory circuits. The identified epigenetic signatures encompass dysregulation of DNA methyltransferases (DNMTs), RNA modifications, histone post-translational modifications and locus-specific alterations, including aberrant methylation at the brain-derived neurotrophic factor (BDNF), opioid μ receptor and transient receptor potential ankyrin 1 (TRPA1) gene loci. Additionally, they involve dysfunction of the glucocorticoid receptor (GR)/corticotropin-releasing factor (CRF) axis via epigenetic modulation. Building on these findings, we evaluate therapeutic strategies addressing epigenetic dysregulation. While preclinical data demonstrate the efficacy of histone deacetylase (HDAC) and DNMT inhibitors, clinical translation faces significant barriers, including limited blood-brain barrier permeability. Notably, our analysis highlights the benefits of combining pharmacological interventions with non-invasive neuromodulation for enhanced co-morbidity management. Looking forward, this review proposes innovative approaches that leverage CRISPR-based chromatin editing platforms, biomimetic nanocarriers for neuron-specific delivery and closed-loop neuromodulation integrating real-time biomarker feedback, collectively establishing a precision medicine framework for pain or neuropsychiatric co-morbidities. Show less
no PDF DOI: 10.1111/bph.70302
BDNF chronic pain epigenetic dysregulation epigenetic mechanisms maladaptive neuroplasticity neuroplasticity neuropsychiatric nociceptive sensitization
Qinfen Chen, Xiaozhen Ding, Yongmin Wei +4 more · 2026 · Brain and behavior · Wiley · added 2026-04-24
To develop and assess the efficacy of a rehabilitation-cognition integrated care (RCIC) program for elderly patients with lower limb fractures and mild-to-moderate cognitive impairment. A total of 128 Show more
To develop and assess the efficacy of a rehabilitation-cognition integrated care (RCIC) program for elderly patients with lower limb fractures and mild-to-moderate cognitive impairment. A total of 128 eligible patients during January 2023 to December 2024 were randomly allocated to conventional (n = 64) or integrated care group (n = 64). Both groups received 12 weeks of intervention. Outcomes, including Fugl-Meyer Assessment (FMA), Berg Balance Scale (BBS), Montreal Cognitive Assessment (MoCA), Functional Independence Measure (FIM), and Hospital Anxiety and Depression Scale (HADS) scores, were compared. Serum neurotrophic and neuroinflammatory markers were analyzed pre- and post-intervention. Complications, fall recurrence rates, and nursing satisfaction were recorded. Post-intervention, both groups showed improved FMA, BBS, and FIM scores, with significantly greater improvement in the integrated care group (p < 0.05). HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D) scores decreased significantly more in the integrated care group (p < 0.05). The integrated care group demonstrated higher MoCA scores versus both its own baseline and the conventional care group post-intervention (p < 0.05). Serum BDNF and GDNF levels increased significantly in the integrated care group compared to both time-matched controls and its baseline (p < 0.05), while S100-β and IL-6 levels decreased significantly (p < 0.05). The integrated care group had lower overall complication rates (p < 0.05), comparable fall recurrence (p > 0.05), and higher nursing satisfaction (p < 0.05). The RCIC program significantly enhances motor function, balance, cognition, and psychological status while reducing complications and improving satisfaction in elderly fracture patients with cognitive impairment. Show less
📄 PDF DOI: 10.1002/brb3.71184
BDNF
Dong Liu, Hongyan Yang, Xiangqian Feng +13 more · 2026 · Experimental gerontology · Elsevier · added 2026-04-24
Alzheimer's disease (AD) and osteoporosis are common age-related degenerative diseases. Emerging evidence suggests that amyloid-β (Aβ) deposition may contribute to the pathogenesis of both conditions. Show more
Alzheimer's disease (AD) and osteoporosis are common age-related degenerative diseases. Emerging evidence suggests that amyloid-β (Aβ) deposition may contribute to the pathogenesis of both conditions. This study investigated whether probucol could alleviate AD-associated bone loss and Aβ42-induced osteoblast dysfunction, and further explored the underlying mechanisms. Female mice were divided into four groups (n = 5 per group): C57BL/6 wild-type (WT), WT treated with probucol (WT + PBC), APP/PS1 transgenic (AD) mice, and AD treated with probucol (AD+PBC). Bone mineral density (BMD) was assessed by micro-CT. Levels of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) along with bone metabolism markers including fibroblast growth factor 23 (FGF23), sclerostin, and brain-derived neurotrophic factor (BDNF) in bone and brain tissues were measured by ELISA. FOXO3a was knocked down in the bone marrow of APP/PS1 mice via stereotactic injection of lentiviral vectors. Expression of APP and FOXO3a in bone tissue was evaluated using RT-qPCR and Western blotting (WB). Mitochondrial damage in osteoblasts and neuronal cells was assessed by transmission electron microscopy (TEM). In vitro study, osteoblast differentiation and mineralization deficits were evaluated using Alizarin Red staining. WB was used to measure the expression of AKT, FOXO3a, autophagy and apoptosis related proteins. Probucol attenuated bone loss and mitochondrial damage in both APP/PS1 and FOXO3a-knockdown APP/PS1 mice, and improved cognitive impairment and neuronal ultrastructure in APP/PS1 mice. Furthermore, probucol attenuated Aβ42-induced osteoblast differentiation and mineralization via the AKT/FOXO3a signaling pathway in vitro. These findings demonstrate that probucol ameliorates AD-associated bone loss and Aβ42-induced osteoblast impairments by regulating AKT/FOXO3a signaling pathway. Show less
no PDF DOI: 10.1016/j.exger.2026.113034
BDNF alzheimer's disease amyloid bone loss osteoblast osteoporosis pathogenesis signaling pathway
Lucheng Xie, Dudu Liu, Zhiyong Liu +8 more · 2026 · Advanced materials (Deerfield Beach, Fla.) · Wiley · added 2026-04-24
Maintaining nerve integrity and rescuing/regenerating injured neurons are pivotal for spinal cord injury (SCI) repair. Herein, an immuno-neuroprotectant (INPT) is developed to mitigate secondary SCI a Show more
Maintaining nerve integrity and rescuing/regenerating injured neurons are pivotal for spinal cord injury (SCI) repair. Herein, an immuno-neuroprotectant (INPT) is developed to mitigate secondary SCI and promote neuroregeneration via sequestration of neutrophil extracellular traps (NETs) and targeted delivery of brain-derived neurotrophic factor (BDNF). To construct the INPT, positively charged BDNF is engineered into negatively charged A-BDNF nanoparticles (A-BDNF NPs) via reversible modification with adenosine triphosphate, and A-BDNF NPs are further coated with polySia-overexpressing microglia membrane (PBM). In SCI mice, intravenously injected INPT effectively accumulates in the injured spinal cord and then binds to NETs through the over-expressed polySia on PBM. This binding triggers PBM shedding from the NPs, and thereby, phosphatidylserine localized at the cytoplasmic leaflet of PBM is exposed and displayed on the NETs surface. Consequently, the PBM-bound NETs are cleared by phagocytes via efferocytosis, which provokes neuroprotective immune responses. Meanwhile, the mildly acidic environment triggers traceless restoration of A-BDNF NPs to the native BDNF to foster neuroregeneration. Thus, PBM-mediated NETs sequestration cooperates with BDNF-mediated neuroregeneration to restore neurological recovery. This study provides an enlightened approach for remedying NET-associated pathophysiological aberrations and also renders a facile yet effective platform for biomacromolecule delivery to the central nervous system. Show less
no PDF DOI: 10.1002/adma.202518580
BDNF brain-derived neurotrophic factor nanoparticles neuroprotectants neuroregeneration neurotrophic factor neutrophil extracellular traps spinal cord injury
Yan Zhao, Yixin Fu, Tianhao Liu +11 more · 2026 · CNS neuroscience & therapeutics · Wiley · added 2026-04-24
Alcohol use disorder (AUD) is a chronic condition marked by compulsive drinking and withdrawal-related negative affect. Histamine (HA) signaling, particularly via the histamine H3 receptor (H3R), may Show more
Alcohol use disorder (AUD) is a chronic condition marked by compulsive drinking and withdrawal-related negative affect. Histamine (HA) signaling, particularly via the histamine H3 receptor (H3R), may modulate alcohol-related behaviors. We investigated the effects of pitolisant, an FDA-approved H3R antagonist, on ethanol (EtOH)-related behaviors in mice. Adult male C57BL/6J mice underwent acute or chronic (2 or > 8 weeks) intermittent alcohol exposure. Pitolisant pretreatment was administered, and then pharmacological behavior, histologic, and molecular assays were conducted. Pitolisant administration reduced acute EtOH-induced locomotor activation, conditioned place preference, and sedative effects, and also curtailed EtOH intake. It alleviated anxiety and depression-like behavior during 24-h withdrawal (Post-EtOH). Mechanistically, the Post-EtOH condition was featured by complicated brain cFos expression mapping, including elevated cFos, [HA] and [glutamine]/[glutamate] ratio in the lateral habenula (LHb). However, systemic pitolisant treatment significantly increased [norepinephrine]/[normetanephrine] ratio, and restored the diminished phosphorylated CREB and BDNF levels in the LHb. Intra-LHb H2R antagonist cimetidine infusion partly blocked the pitolisant therapeutic effect on alcohol-related behavior. These findings highlight the HAergic system as a critical regulator of alcohol-related behaviors. The LHb HA signaling and norepinephrine neurotransmission might underlie pitolisant's potential novel therapeutic strategy for AUD. Show less
📄 PDF DOI: 10.1002/cns.70732
BDNF
Yichen Xie, Fusheng Gao, Ying Geng +4 more · 2026 · Journal of ethnopharmacology · Elsevier · added 2026-04-24
Enhancing memory and alleviating amnesia are among the conditions that Ganoderma lucidum has historically been used to treat. However, there are relatively few studies on the potential therapeutic eff Show more
Enhancing memory and alleviating amnesia are among the conditions that Ganoderma lucidum has historically been used to treat. However, there are relatively few studies on the potential therapeutic effects of active ingredients derived from Ganoderma lucidum in the treatment of memory impairment. This study investigated the ameliorative effect of Lucidenic acid A (LAA) on memory impairment via in vivo and in vitro experiments using experimental pharmacology approaches. In vivo, behavioral tests were used to evaluate memory impairment in mice. Transmission electron microscopy, Hematoxylin-Eosin (HE) staining, and Nissl staining were employed to observe pathological changes in mice. Western blotting (WB) was used for protein expression analysis. In vitro, CCK-8 assay and cell scratch test were used to evaluate changes in cell viability. Reactive oxygen species (ROS) immunofluorescence staining was used to assess intracellular oxidative stress changes. WB was also used for protein expression analysis. The results show that LAA can not only improve spatial learning and memory abilities and alleviate cholinergic system impairments in mice with memory impairment, but also mitigate oxidative stress and inflammatory responses, and reduce pathological changes in brain tissue. In addition to improving memory impairment in mice, LAA can also alleviate inflammation, oxidative stress, and neuronal apoptosis induced in cells. LAA can induce the activation of the PI3K/AKT/BDNF pathway, thereby alleviating inflammation, oxidative stress, and cholinergic system impairments caused by scopolamine (SCOP) administration, and improving memory impairment. Show less
no PDF DOI: 10.1016/j.jep.2025.121099
BDNF amnesia cellular nerve damage ganoderma lucidum lucidenic acid a memory impairment neuroprotection pi3k/akt/bdnf signaling
Jiyang Li, Jiancheng Xu, Yixin Xu +9 more · 2026 · European journal of pharmacology · Elsevier · added 2026-04-24
Substance use disorder is characterized by compulsive seeking behavior that is associated with aberrant synaptic plasticity in mature neurons. Environmental enrichment (EE) has been shown to increase Show more
Substance use disorder is characterized by compulsive seeking behavior that is associated with aberrant synaptic plasticity in mature neurons. Environmental enrichment (EE) has been shown to increase adult hippocampal neurogenesis and exert beneficial effects on addictive behaviors. However, the mechanisms of EE's effects on methamphetamine (METH)-induced synaptic plasticity in mature and newborn neurons remain unclear. We reported that EE decreased METH-induced seeking behavior with a decrease in the activity of mature granule cells and an increase in the number of newborn granule cells. Furthermore, the aberrant glutamatergic transmission in hippocampal mature and newborn granule cells was differentially regulated by EE. Moreover, EE restored the normal synaptic plasticity, accompanied by enhancement of brain derived neurotrophic factor (BDNF) expression. Importantly, the intervention of BDNF reversed the effects of EE on METH-induced reinstatement behavior and glutamatergic transmission in both mature and newborn cells. Finally, specifically knocking out the newborn neurons reversed the changes of EE in abnormal plasticity of mature neurons, as well as in seeking and cognitive behaviors. Taken together, regulating synaptic plasticity of mature and newborn neurons is involved in METH-induced seeking behavior and cognitive impairments, which highlights a critical role of adult neurogenesis in the treatment of METH addiction. Show less
no PDF DOI: 10.1016/j.ejphar.2025.178496
BDNF addictive behaviors environmental enrichment hippocampal methamphetamine neurogenesis neuronal plasticity neuroscience
Dongbo Han, Guili Zhou, Dongmei Li +4 more · 2026 · Chemistry & biodiversity · Wiley · added 2026-04-24
Depression is a debilitating psychiatric disorder with high prevalence and suicide risk, imposing significant burdens on global health. Against this global health burden, the active ingredients of Gek Show more
Depression is a debilitating psychiatric disorder with high prevalence and suicide risk, imposing significant burdens on global health. Against this global health burden, the active ingredients of Gekko gecko Linnaeus (AIGG), a traditional Chinese medicine (TCM), have shown empirical antidepressant effects. However, their specific pharmacological mechanisms remain unclear. This study systematically elucidated the antidepressant mechanisms of AIGG by integrating GC-MS-based component analysis, network pharmacology, molecular docking, and a corticosterone (CORT)-induced depressive mouse model. GC-MS identified 10 bioactive compounds (including fatty acids) in AIGG. Network pharmacology screening of 51 potential targets revealed significant enrichment in synaptic transmission and cAMP pathways. Molecular docking confirmed strong binding affinities between AIGG-derived compounds and key targets. In vivo experiments demonstrated that AIGG significantly reversed depression-like behaviors in both forced swim and tail suspension tests, suppressed Interleukin-6 (IL-6), tumor necrosis factor α (TNF-α), and elevated β-nerve growth factor (β-NGF) levels, attenuated neuroinflammatory infiltration and neuronal apoptosis in brain tissue, and upregulated protein expression of protein kinase cAMP-activated catalytic subunit alpha (PRKACA), brain-derived neurotrophic factor (BDNF), and postsynaptic density protein 95 (PSD95). The study confirmed that AIGG alleviates depression by activating the cAMP-PRKACA-BDNF axis to restore synaptic plasticity, providing a novel natural product-based strategy for treatment of the resistant depression. Show less
no PDF DOI: 10.1002/cbdv.202502015
BDNF antidepressant depression omics pharmacology psychiatric disorder signaling traditional chinese medicine
Zev M Nakamura, Brent J Small, Xingtao Zhou +18 more · 2026 · Journal of geriatric oncology · Elsevier · added 2026-04-24
no PDF DOI: 10.1016/j.jgo.2025.102834
BDNF bdnf breast cancer cognition genotype neuroscience oncology psychology
Shounan Lu, Shanjia Ke, Hongjun Yu +18 more · 2026 · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · Wiley · added 2026-04-24
Cancer-associated fibroblasts (CAFs) drive immunosuppression in hepatocellular carcinoma (HCC). However, their metabolic regulation remains poorly defined. We investigated the role of nicotinamide N-m Show more
Cancer-associated fibroblasts (CAFs) drive immunosuppression in hepatocellular carcinoma (HCC). However, their metabolic regulation remains poorly defined. We investigated the role of nicotinamide N-methyltransferase (NNMT) in CAFs. High NNMT expression in CAF tissues was confirmed by western blotting and immunofluorescence staining. Primary CAFs from HCC patients, single-cell RNA-seq (GSE149614), patient-derived organoids (PDOs), and fibroblast-specific NNMT-knockout mice were integrated by metabolomic analyses. NNMT in CAFs binds EZH2 and impedes its nuclear translocation, thereby reducing H3K27me3 enrichment at the promoter of angiopoietin-like 4 (ANGPTL4) to increase ANGPTL4 secretion. Secreted ANGPTL4 engages GLUT1 in HCC cells, activating aerobic glycolysis and increasing histone H3K18la levels. This epigenetic reprogramming transcriptionally upregulates PD-L1 expression, thereby facilitating tumor immune evasion. Additionally, CAF-derived ANGPTL4 promotes angiogenesis in HCC. Therapeutically, targeting the NNMT-ANGPTL4 axis restored CD8 We identified an NNMT-ANGPTL4-driven metabolic-epigenetic cascade in CAFs that induces PD-L1-mediated immune evasion, providing a therapeutic strategy to overcome resistance to immunotherapy in patients with HCC. Show less
no PDF DOI: 10.1002/advs.202521418
ANGPTL4
Xinpeng Li, Siqi Jin, Hong Hu +18 more · 2026 · Frontiers in microbiology · Frontiers · added 2026-04-24
Protein feed resource shortage is a major constraint to the sustainable development of the livestock industry and a bottleneck problem hindering the growth of the Tibetan pig industry in China's Qingh Show more
Protein feed resource shortage is a major constraint to the sustainable development of the livestock industry and a bottleneck problem hindering the growth of the Tibetan pig industry in China's Qinghai-Tibet Plateau region. Walnut meal, rich in protein, holds promise as a substitute for soybean meal. However, the effects and underlying mechanisms of walnut meal substitution on Tibetan pigs in Diqing remain unclear. The study showed that substituting 50% of soybean meal with walnut meal in the diet of Diqing Tibetan pigs significantly reduced backfat thickness and increased intramuscular fat content ( This study reveals that walnut meal can serve as a substitute for soybean meal, and a 50% substitution ratio is conducive to intramuscular fat deposition in Diqing Tibetan pigs. The findings provide valuable insights for the development and application of unconventional protein feed resources, and offer new perspectives for the production of marbled pork. Show less
📄 PDF DOI: 10.3389/fmicb.2026.1794046
ANGPTL4
Jin Zhang, Tian Wei, Yong-Wei Xiong +11 more · 2026 · Science advances · Science · added 2026-04-24
Recently, the perspective of paternal origin has emerged, yet its role in motor disorders remains unclear. Here, using
📄 PDF DOI: 10.1126/sciadv.aea8321
ANGPTL4
Ziwen Li, Lipeng Guan, Tong Mu +11 more · 2026 · Diabetes · added 2026-04-24
Diabetic retinopathy (DR) is a leading cause of vision loss in working-age adults and often progresses to proliferative diabetic retinopathy (PDR) with irreversible complications. Anti-vascular endoth Show more
Diabetic retinopathy (DR) is a leading cause of vision loss in working-age adults and often progresses to proliferative diabetic retinopathy (PDR) with irreversible complications. Anti-vascular endothelial growth factor (VEGF) therapy remains the first-line treatment; however, resistance poses a significant challenge, necessitating alternative therapeutic targets. This study explores the role of angiopoietin-like protein 4 (ANGPTL4) in PDR pathogenesis, emphasizing vascular-immune-lymphatic interactions. We found significantly elevated ANGPTL4 and VEGF-C levels in the vitreous humor of patients with PDR, which were not affected by anti-VEGF therapy. In vivo, full-length ANGPTL4 and its C-terminal fragment promoted pathological angiogenesis and lymphatic-like remodeling in diabetic murine retinas, characterized by increased lymphatic vessel endothelial hyaluronan receptor 1, prospero homeobox 1, and VEGF receptor 3 (VEGFR3) expression. Single-cell sequencing further revealed ANGPTL4-driven immune dysregulation, with abnormal infiltration of CD4+ T cells and dendritic cells. Knockdown of ANGPTL4 in mice with oxygen-induced retinopathy alleviated retinal hypoxia, neovascularization, and vascular leakage. Mechanistically, retinal hypoxia markedly increased ANGPTL4 expression levels in the retina, which activated the activator protein-1 (AP-1) transcription factor complex and promoted Cd83 transcription in mouse heart microvascular endothelial cells. Additionally, ANGPTL4 bound to neuropilin-1 (NRP1)/VEGFR3, driving human lymphatic endothelial cell proliferation and lymphatic vessel ingrowth from the optic nerve sheath into the retina, a finding that suggests a novel pathway independent of angiopoietin-Tie signaling. These findings establish ANGPTL4 as a key mediator of immune-vascular interactions in PDR and a potential therapeutic target to address both pathological angiogenesis and lymphatic dysfunction. Some patients with proliferative diabetic retinopathy (PDR) have poor responses to anti-vascular endothelial growth factor (anti-VEGF) therapy. This situation highlights the need for additional therapeutic approaches. In proliferative diabetic retinopathy, what is the role of ANGPTL4 that differs from VEGF? We found that ANGPTL4 is elevated in the vitreous humor of patients with PDR who are poorly responsive to anti-VEGF therapy. ANGPTL4, particularly its C-terminal fragment, causes retinal lymphatic-like remodeling in diabetic mice. This study provides novel insights into the complex interplay between immune activation, neovascularization, and lymphatic-like remodeling in PDR. Our findings deepen our understanding of PDR pathophysiology and propose a promising therapeutic target. Show less
no PDF DOI: 10.2337/db25-0445
ANGPTL4
Yuyan Gu, Yao Jin, Huashan Zhao +10 more · 2026 · Phytomedicine : international journal of phytotherapy and phytopharmacology · Elsevier · added 2026-04-24
Atherosclerosis is the pathological basis of cardiovascular diseases. Dingxin Recipe III (DXRIII), a traditional Chinese herbal formula, has shown therapeutic effect for atherosclerosis, though its me Show more
Atherosclerosis is the pathological basis of cardiovascular diseases. Dingxin Recipe III (DXRIII), a traditional Chinese herbal formula, has shown therapeutic effect for atherosclerosis, though its mechanisms remain unclear. This study aimed to investigate the effects and molecular mechanisms of DXRIII on atherosclerosis progression. Male ApoE DXRIII significantly reduced aortic plaque areas, improved lipid profiles (decreased triglycerides, total cholesterol, and low-density lipoprotein-C), and alleviated hepatic steatosis. Integrated multi-omics revealed modulation of lipid metabolism pathways, including steroid hormone biosynthesis and arachidonic acid metabolism pathways. Steroidogenic acute regulatory-related lipid transfer protein 4 (Stard4) was identified as a key target, with expression positively correlated with gamma-linolenic acid and negatively correlated with corticosterone. Direct binding between DXRIII components and Stard4 was observed. Stard4 overexpression reduced lipid accumulation, while knockdown aggravated lipid deposition and negated the effect of DXRIII. Hepatic Stard4 knockdown aggravated atherosclerosis and lipid-related genes expression (Angptl4, Apob, Soat2, Scarb1, Lepr). DXRIII attenuates atherosclerosis by upregulating hepatic Stard4 expression to restore lipid homeostasis and reduce lipid accumulation. Show less
no PDF DOI: 10.1016/j.phymed.2026.157924
ANGPTL4
Yichuan Lin, Zhicong Zhang, Jiahao Zhang +6 more · 2026 · Comparative biochemistry and physiology. Part A, Molecular & integrative physiology · Elsevier · added 2026-04-24
With global climate warming increasingly threatening aquatic ecosystems, prolonged exposure to high temperatures has become a major environmental stressor for both wild and cultured fish. However, the Show more
With global climate warming increasingly threatening aquatic ecosystems, prolonged exposure to high temperatures has become a major environmental stressor for both wild and cultured fish. However, the long-term effects of chronic heat stress on blood physiology and hematopoietic processes remain poorly understood. To assess the long-term impacts of chronic heat stress on hematopoiesis in largemouth bass (Micropterus salmoides), we conducted a 180-day acclimation experiment at 34 °C. Hematological analyses showed significant reductions in red blood cell counts and hemoglobin concentrations, indicating impaired oxygen transport capacity. Blood cell morphology was altered, with erythrocytes exhibiting a lower major-to-minor axis ratio and leukocytes (lymphocytes and granulocytes) showing increased volumes. Histological and ultrastructural observations of the head kidney revealed tissue loosening, hemosiderin deposition, mitochondrial damage, and elevated apoptosis. Furthermore, transcriptomic analysis combined with GO and KEGG enrichment revealed that pathways involved in vascular development, stress response, and fatty acid metabolism were significantly activated under heat stress. Notably, key genes associated with angiogenesis, lipid metabolism, stimuli response, apoptosis and immunity, including mmp9, angptl4, abca1 and stab2, were markedly upregulated, suggesting their crucial roles in vascular remodeling and thermotolerance. Together, these results provide the first integrative cellular and molecular characterization of hematopoietic responses to prolonged high temperature in M. salmoides. The findings enhance understanding of fish physiological plasticity under environmental stress and have implications for aquaculture management and the development of heat-resilient strains. Show less
no PDF DOI: 10.1016/j.cbpa.2026.111973
ANGPTL4
Qiong Lu, Qiyue Zheng, Zhaokai Zhou +7 more · 2026 · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · Wiley · added 2026-04-24
Bone angiogenesis is important for bone formation and regeneration after bone injury. Endothelial-derived angiogenic factors are key signal transducers in the bone microenvironment and maintain vascul Show more
Bone angiogenesis is important for bone formation and regeneration after bone injury. Endothelial-derived angiogenic factors are key signal transducers in the bone microenvironment and maintain vascular-osteogenic coupling during bone regeneration. CGRP, a bone sensory neuron-derived peptide, contributes to bone formation, but the potential mechanism by which it improves bone regeneration via angiogenesis is unclear. Here, we demonstrate that CGRP may contribute to bone repair in the elderly, as human CGRP levels are inversely proportional to age and proportional to bone mass in clinical data and bulk transcriptome data. Based on single-cell RNA sequencing data and experimental analyses, CGRP is found to promote the angiogenesis of human microvascular endothelial cell line-1 in vitro through the FAK-AKT-VEGF pathway. CGRP gene deletion in mice reduced bone vascular density and bone mass, and delayed angiogenesis and bone regeneration at the bone defect site. Recombinant CGRP restored bone repair after defect introduction. It also promoted Angptl4 secretion by bone vascular endothelial cells, thereby driving osteogenic differentiation of bone marrow mesenchymal stem cells and enhancing bone regeneration after bone injury. Treatment with recombinant Angptl4 enhanced bone healing in a mouse bone defect model. These integrated analysis reveal the important role and mechanism of CGRP in vascular-mediated osteogenesis, suggesting a novel therapeutic strategy for promoting bone regeneration. Show less
📄 PDF DOI: 10.1002/advs.202522295
ANGPTL4
Qiang Li, Zhiqi Liao, Xinyao Hu +26 more · 2026 · Molecular therapy : the journal of the American Society of Gene Therapy · Elsevier · added 2026-04-24
Clinical application of mesenchymal stem cells for endometrial repair has been hampered by variability in cell quality, large-scale production, and uncertainty regarding the optimal delivery route. In Show more
Clinical application of mesenchymal stem cells for endometrial repair has been hampered by variability in cell quality, large-scale production, and uncertainty regarding the optimal delivery route. In this study, we investigated the therapeutic potential of clinical-grade human embryonic stem cell-derived immunity-and-matrix-regulatory cells (IMRCs) for treating refractory moderate-to-severe intrauterine adhesion (IUA). In a rabbit IUA model, sub-endometrial injection of IMRCs significantly reduced fibrosis and enhanced endometrial angiogenesis, outperforming uterine perfusion. Transcriptomic analysis revealed distinct pro-angiogenic gene expression profiles between the two delivery routes. In vitro, IMRCs co-cultured with endometrial stromal cells (ESCs) markedly enhanced angiogenic potential compared to either cell type alone. Protein array analysis of the co-culture supernatant showed elevated levels of angiogenic factors, with functional assays confirming that inhibition of ANGPTL4, a non-canonical pro-angiogenic mediator, impaired angiogenesis. In a first-in-human, single-center, phase 1 dose-escalation trial involving 18 patients with refractory IUA, high-dose sub-endometrial IMRC injection promoted angiogenesis, reduced uterine scarring, and improved pregnancy outcomes, with no safety concerns observed over 3 years of follow-up. These findings highlight the translational promise of IMRCs as a novel therapeutic strategy for endometrial regeneration in severe IUA. Show less
📄 PDF DOI: 10.1016/j.ymthe.2025.09.035
ANGPTL4
Ya-Xin Deng, Bao-Jun Ding, Hong-Chun Li +4 more · 2026 · Yi chuan = Hereditas · added 2026-04-24
The
no PDF DOI: 10.16288/j.yczz.25-190
APOA4
Na Huang, Heming Wang, Xiao Li +8 more · 2026 · Lipids in health and disease · BioMed Central · added 2026-04-24
Significant interindividual variability in radiosensitivity poses a major challenge to conventional radiation protection and radiotherapy. Current prediction strategies relying on DNA damage or genomi Show more
Significant interindividual variability in radiosensitivity poses a major challenge to conventional radiation protection and radiotherapy. Current prediction strategies relying on DNA damage or genomic analysis have inherent limitations, underscoring the need for minimally invasive serum biomarkers. While serum apolipoproteins are crucial regulators of lipid transport, metabolism, and cellular stress response, their role as biomarkers for radiosensitivity remains largely unexplored. A 7.3 Gy ⁶⁰Co γ-ray whole-body irradiation mouse model (with training and independent validation cohorts) was established to assess individual radiosensitivity. Pre-irradiation peripheral serum samples underwent high-throughput proteomics analysis to identify differential proteins (DEPs) linked to 30-day post-irradiation survival. KEGG and GO enrichment analyses were conducted to characterize DEP-associated pathways. An XGBoost machine learning model was built using candidate biomarkers, with SHAP analysis to define their predictive contributions; Cox proportional hazards and Pearson correlation analyses were applied to evaluate survival associations. DIA-based proteomics identified 580 DEPs in the training cohort and 449 in the validation cohort. KEGG and GO enrichment analyses confirmed that these DEPs were predominantly enriched in the cholesterol metabolism and reverse cholesterol transport pathways. The predictive model based on an apolipoprotein panel (ApoA1/ApoA2/ApoA4), established using the XGBoost algorithm, exhibited exceptional performance in the training cohort (AUC = 1) and maintained robust generalizability in an independent validation cohort (AUC = 0.833). Compared with non-survivors, survivors exhibited significantly elevated serum levels of ApoA1 and ApoA2 but markedly reduced levels of ApoA4. Cox proportional hazards regression analysis established ApoA1 and ApoA2 as independent protective factors, whereas high ApoA4 expression was an adverse prognostic indicator. Notably, ApoA4 levels also demonstrated a strong negative correlation with post-irradiation survival time. The serum apolipoprotein profile (ApoA1/ApoA2/ApoA4) serves not only as a promising minimally invasive biomarker for predicting individual radiosensitivity in mice but also reveals a critical link between the cholesterol metabolic pathway and radiation response. This finding lays a theoretical foundation for translating predictive, cholesterol metabolism-related biomarkers to support radiation response assessments. Given the limitations of animal models, subsequent studies are required to validate the clinical applicability of this panel in human cohorts, with the aim of offering an effective tool for personalized radiation protection and precise radiotherapy. The online version contains supplementary material available at 10.1186/s12944-026-02868-8. Show less
📄 PDF DOI: 10.1186/s12944-026-02868-8
APOA4
Lu Cao, Gang Chen, Jing Zhou +5 more · 2026 · Biomedical reports · added 2026-04-24
Amyotrophic lateral sclerosis (ALS) is a heterogeneous neurodegenerative disorder. Notably, the differences in lipid metabolism between bulbar- and limb-onset subtypes of ALS remain unclear, particula Show more
Amyotrophic lateral sclerosis (ALS) is a heterogeneous neurodegenerative disorder. Notably, the differences in lipid metabolism between bulbar- and limb-onset subtypes of ALS remain unclear, particularly in non-Western populations. The present study investigated serum lipid profiles in a Chinese cohort of patients with ALS to explore their associations with disease severity and clinical subtypes. A retrospective, cross-sectional study was conducted, involving 158 patients with ALS and 62 matched healthy controls. Serum lipid parameters, including total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), small dense LDL cholesterol (sdLDL-c), apolipoprotein A-1 (ApoA1), apolipoprotein B (ApoB) and the TG/HDL ratio, were compared between the groups. Correlation analyses and multivariable linear regression models incorporating phenotype x lipid interaction terms were conducted after adjusting for age, sex, body mass index and disease duration. Patients with ALS exhibited significantly higher TC, TG, LDL, sdLDL-c, ApoA1, ApoB and TG/HDL ratios than controls. Subtype-specific analyses revealed different associations; in bulbar-onset ALS, higher sdLDL-c and TG/HDL ratios were associated with better functional status, whereas higher HDL and ApoA1 levels were negatively correlated with functional status. By contrast, in limb-onset ALS, higher sdLDL-c and ApoB levels were associated with worse function. Interaction analyses confirmed significant phenotype modification for sdLDL-c, TG/HDL ratio, HDL and ApoA1. These results suggest that lipid-severity relationships in ALS vary by subtype, indicating metabolic heterogeneity across phenotypes and supporting the potential of specific lipid parameters as exploratory markers for disease monitoring. Show less
📄 PDF DOI: 10.3892/br.2026.2141
APOB
Yaqun Fang, Zhiye Zhang, Qiqi Cao +20 more · 2026 · Arteriosclerosis, thrombosis, and vascular biology · added 2026-04-24
ApoB (apolipoprotein B)-containing lipoproteins are causal risk factors for atherosclerotic coronary artery disease (CAD). Since human cathelicidin LL-37 binds to ApoB-100 in this pathological context Show more
ApoB (apolipoprotein B)-containing lipoproteins are causal risk factors for atherosclerotic coronary artery disease (CAD). Since human cathelicidin LL-37 binds to ApoB-100 in this pathological context, we investigated whether the circulating LL-37-ApoB-100 complex could serve as a biomarker for CAD. We performed surface plasmon resonance and protein-protein docking to demonstrate the direct LL-37-ApoB-100 interaction. We developed a specific polyclonal antibody against the complex and measured its levels in human atherosclerotic plaques and plasma, as well as in We identified that LL-37 directly interacted with multiple distinct binding sites on ApoB-100. Plasma levels of LL-37-ApoB-100 complex were significantly elevated in human patients with atherosclerosis. Consistently, levels of this complex were positively correlated with atherosclerotic plaque area in Circulating LL-37-ApoB-100 levels are strongly associated with angiographically documented CAD, highlighting LL-37-ApoB-100 as an independent predictor for CAD. Show less
no PDF DOI: 10.1161/ATVBAHA.125.323486
APOB
Min Zuo, Haixia Xu, Yuying Yang +7 more · 2026 · Communications biology · Nature · added 2026-04-24
Adolescent Idiopathic Scoliosis (AIS) is the most common form of spinal deformity among adolescents. To explore its etiology of progression and scoliosis-modifying drugs, chondrocytic senescence was c Show more
Adolescent Idiopathic Scoliosis (AIS) is the most common form of spinal deformity among adolescents. To explore its etiology of progression and scoliosis-modifying drugs, chondrocytic senescence was confirmed in AIS facet joint cartilage by analyzing clinical specimen. Furthermore, through 4D/480 label-free proteomics analysis, we identified an exosome-mediated positive feedback loop during scoliosis progression, which driving the elevation of cholesterol flow between spinal cartilage and vertebra. To further investigate the pathological significance of the loop in vivo, high-cholesterol flow was reconstructed in C57BL/6 J mice by injecting with recombinant adeno-associated virus rAAV9-Runx2-HMGCR. Our results confirmed the important role of the positive feedback loop in the development of scoliosis. Meanwhile, Avasimibe or/and Corylin were used to delay the scoliosis progression by targeting the key exosomal proteins APOB (Apolipoprotein B-100) or/and HSP90β (Heat Shock Protein 90-beta). This research extends the etiology of scoliosis progression and provides an alternative perspective for scoliosis non-surgical treatment. Show less
📄 PDF DOI: 10.1038/s42003-026-09960-w
APOB
Wei Pan, Xiaozhao Lu, Ziwei Zhou +14 more · 2026 · Lipids in health and disease · BioMed Central · added 2026-04-24
Residual cardiovascular risk persists in statin-treated patients with coronary artery disease (CAD), even when low-density lipoprotein cholesterol (LDL-C) targets are met. Excess apolipoprotein B (apo Show more
Residual cardiovascular risk persists in statin-treated patients with coronary artery disease (CAD), even when low-density lipoprotein cholesterol (LDL-C) targets are met. Excess apolipoprotein B (apoB), defined as measured apoB minus LDL-C-predicted apoB, may capture atherogenic particle burden beyond LDL-C, but its prognostic value for long-term mortality in secondary prevention remains uncertain. We conducted a pooled analysis of two nationwide Chinese cohorts (CIN-II and RED-CARPET) comprising 68,616 statin-treated CAD patients. Excess apoB was calculated using an internal reference population (triglycerides ≤ 1.0 mmol/L). Associations with all-cause and cardiovascular mortality were assessed using multivariable Cox models, with adjustment for clinical covariates including nutritional status. External validation was performed in 13,702 participants from the UK Biobank. Over a median follow-up of 5.2 years, 10,835 deaths occurred (5,090 cardiovascular). Each 1-standard deviation (15.4 mg/dL) increase in excess apoB was associated with a 12% higher risk of all-cause mortality (adjusted hazard ratio [aHR] 1.12, 95% CI 1.06-1.18) and a 24% higher risk of cardiovascular mortality (aHR 1.24, 95% CI 1.15-1.34). Patients in the highest excess apoB quartile (≥ 11.5 mg/dL) had significantly worse survival. Notably, these associations persisted consistently across all achieved LDL-C strata (< 2.0 to > 4.0 mmol/L). These findings were robustly confirmed in the external validation cohort. Excess apoB is an independent predictor of long-term mortality in statin-treated CAD patients, even among those with well-controlled LDL-C. Its incorporation into risk assessment could improve prognostic stratification and guide personalized management in secondary prevention. CIN-II: ClinicalTrials.gov, NCT05050877 (Retrospectively registered, 21 September 2021); RED-CARPET: Chinese Clinical Trial Registry, ChiCTR2000039901 (Prospectively registered, 14 November 2020). The UK Biobank study is covered by generic ethical approval from the NHS National Research Ethics Service (Ref: 99231). Show less
no PDF DOI: 10.1186/s12944-026-02928-z
APOB
Yu Wang, Li Chen, Yingze Ma +8 more · 2026 · Nature communications · Nature · added 2026-04-24
Dietary fat absorption is among the most energy-demanding processes of nutrient uptake. Fatty acid activation, triglyceride synthesis, and the trafficking of chylomicrons through the secretory pathway Show more
Dietary fat absorption is among the most energy-demanding processes of nutrient uptake. Fatty acid activation, triglyceride synthesis, and the trafficking of chylomicrons through the secretory pathway - all require ATP. How enterocytes accommodate the surge in ATP consumption following fat uptake is unclear. We show that the purine biosynthesis/salvage pathway supplies necessary ATP and that Ankyrin Repeat Domain 9 (ANKRD9) couples ATP synthesis and lipoprotein trafficking. Ankrd9 regulates enzymes within the purine biosynthesis pathway to increase ATP synthesis and facilitate Golgi dynamics. Intracellular localization of ANKRD9 is lipid and ATP-dependent. Inactivation of Ankrd9 in mice reduces intestinal ATP despite intact mitochondrial and glycolytic function, alters Golgi morphology, delays ApoB/chylomicron trafficking, and causes lipid accumulation in enterocytes, along with a lean body phenotype. Taken together, the results reveal a previously unrecognized mechanism that regulates lipid absorption in enterocytes and identify ANKRD9 as a central component of this mechanism. Show less
no PDF DOI: 10.1038/s41467-026-70332-3
APOB